Virginia Ruth Sanzone Sells 4,856 Shares of ICU Medical (NASDAQ:ICUI) Stock

ICU Medical, Inc. (NASDAQ:ICUI) VP Virginia Sanzone sold 4,856 shares of the firm’s stock in a transaction that occurred on Thursday, September 3rd. The shares were sold at an average price of $168.69, for a total value of $819,158.64. Following the completion of the sale, the vice president directly owned 14,604 shares in the company, valued at $2,463,548.76. This trade represents a 24.95% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

ICU Medical Stock Up 0.8%

Shares of ICUI stock opened at $167.58 on Friday. ICU Medical, Inc. has a 12 month low of $112.50 and a 12 month high of $192.85. The company has a quick ratio of 1.21, a current ratio of 2.43 and a debt-to-equity ratio of 0.56. The firm has a market cap of $4.19 billion, a PE ratio of 142.02, a price-to-earnings-growth ratio of 2.10 and a beta of 0.75. The stock has a 50 day moving average of $167.35 and a 200-day moving average of $144.86.

ICU Medical (NASDAQ:ICUI) last announced its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $2.37 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.91 by $0.46. ICU Medical had a net margin of 1.39% and a return on equity of 7.91%. The business had revenue of $547.88 million for the quarter, compared to the consensus estimate of $533.44 million. During the same quarter last year, the company posted $2.10 earnings per share. ICU Medical’s quarterly revenue was up .5% on a year-over-year basis. ICU Medical has set its FY 2026 guidance at 8.600-9.000 EPS. On average, equities analysts predict that ICU Medical, Inc. will post 7.19 EPS for the current year.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the stock. BTIG Research boosted their price objective on shares of ICU Medical from $170.00 to $200.00 and gave the stock a “buy” rating in a report on Friday, August 7th. KeyCorp lifted their target price on ICU Medical from $164.00 to $182.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 21st. Weiss Ratings upgraded ICU Medical from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Thursday, July 23rd. Raymond James Financial reaffirmed a “strong-buy” rating and issued a $200.00 price target on shares of ICU Medical in a report on Friday, August 7th. Finally, Sanford C. Bernstein downgraded ICU Medical to a “market perform” rating in a research report on Monday, June 15th. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $192.80.

Hedge Funds Weigh In On ICU Medical

A number of hedge funds and other institutional investors have recently made changes to their positions in ICUI. Allworth Financial LP bought a new stake in ICU Medical in the second quarter valued at about $26,000. Hilton Head Capital Partners LLC acquired a new stake in ICU Medical during the fourth quarter valued at approximately $32,000. Public Employees Retirement System of Ohio bought a new stake in shares of ICU Medical in the 2nd quarter valued at approximately $51,000. Covestor Ltd grew its stake in shares of ICU Medical by 22.1% in the 4th quarter. Covestor Ltd now owns 696 shares of the medical instruments supplier’s stock valued at $99,000 after purchasing an additional 126 shares during the period. Finally, Strs Ohio raised its holdings in shares of ICU Medical by 60.0% in the 4th quarter. Strs Ohio now owns 800 shares of the medical instruments supplier’s stock worth $114,000 after buying an additional 300 shares in the last quarter. 96.10% of the stock is owned by institutional investors.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.